Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. SLRX
stocks logo

SLRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2024Q3
FY2025Q1
--
--
-804.000
+15361.53%
--
--
-702.000
+21302.43%
Estimates Revision
The market is revising No Change the revenue expectations for Salarius Pharmaceuticals, Inc. (SLRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -81.52%.
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-81.52%
In Past 3 Month

Valuation Metrics

The current forward P/E ratio for Salarius Pharmaceuticals Inc (SLRX.O) is -0.00, compared to its 5-year average forward P/E of -1.01. For a more detailed relative valuation and DCF analysis to assess Salarius Pharmaceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.01
Current PE
-0.00
Overvalued PE
0.67
Undervalued PE
-2.70

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-0.12
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.65
Undervalued EV/EBITDA
-0.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.42
Current PS
0.00
Overvalued PS
30.79
Undervalued PS
-15.95
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

SLRX News & Events

Events Timeline

(ET)
2025-12-01
08:20:00
Decoy Therapeutics Partners with Texas Biomedical Research Institute for Influenza Inhibitor Testing
select
2025-11-19 (ET)
2025-11-19
14:57:40
Salarius Pharmaceuticals confirms ongoing Nasdaq trading for its shares
select
2025-11-13 (ET)
2025-11-13
08:47:12
Salarius Pharmaceuticals and Decoy Therapeutics Finalize Merger
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
3.5
12-01Globenewswire
Salarius Partners with Texas Biomed to Develop Influenza Inhibitors
  • Collaborative Research: Salarius' subsidiary Decoy Therapeutics partners with Texas Biomed to conduct in vitro testing of influenza fusion inhibitors against various strains, including H5N1 avian flu, showcasing significant market potential.
  • Platform Advantage: Decoy's IMP3ACT platform utilizes machine learning and rapid synthesis techniques to swiftly design and manufacture broad-spectrum antiviral drugs targeting influenza, COVID-19, and RSV, enhancing drug development efficiency and success rates.
  • Market Opportunity: Salarius' CEO highlighted that seasonal influenza and related viruses account for over 10 million medical visits annually, with Merck's $9.2 billion acquisition of Cidara Therapeutics indicating strong interest from big pharma in novel antivirals, suggesting a substantial commercial opportunity for Salarius.
  • Future Plans: Over the next 12 months, Decoy aims to advance its lead asset's IND application and make progress on programs targeting influenza, COVID-19, and RSV, further solidifying its position in the antiviral market.
[object Object]
Preview
8.5
11-20Newsfilter
Salarius Pharmaceuticals Points Out Mistakes on S&P CapIQ Platform After Merging with Decoy Therapeutics, Confirms Its Shares Remain Listed on Nasdaq Under the Symbol "SLRX"

  • Correction of Misinformation: Salarius Pharmaceuticals addresses an error on the S&P CapIQ platform that incorrectly stated the company had been delisted from Nasdaq, confirming that its stock continues to trade under the ticker "SLRX."

  • Recent Financial Activities: The company completed an $8 million public offering and merged with Decoy Therapeutics, resulting in a combined cash position of approximately $14 million and around 5.9 million shares outstanding.

  • Focus on Drug Development: Salarius is advancing Decoy's pipeline of peptide conjugate therapeutics, utilizing its IMP3ACT platform, which incorporates AI and machine learning to streamline drug development.

  • Forward-Looking Statements: The press release includes forward-looking statements regarding the company's future plans and potential risks, emphasizing that actual results may differ from expectations due to various uncertainties.

[object Object]
Preview
2.0
11-13TipRanks
Three Penny Stocks to Keep an Eye on as of November 13, 2025

  • Penny Stocks to Watch: Leap Therapeutics, Amaze Holdings, and Salarius Pharmaceuticals are highlighted as key penny stocks to monitor on November 13, 2025, based on their Dollar Volume and market activity.

  • Leap Therapeutics Update: Leap Therapeutics (LPTX) experienced a significant stock price increase of over 368% after announcing plans to expand into digital asset investments and rebranding to "Cypherpunk Technologies" (CYPH).

  • Amaze Holdings Acquisition: Amaze Holdings (AMZE) saw a nearly 17% drop in stock price despite acquiring The Food Channel's assets for $650,000, aiming to enhance its creator-powered commerce platform.

  • Salarius Pharmaceuticals Recovery: Salarius Pharmaceuticals (SLRX) had a 17.4% stock price gain following a public offering to raise $7 million for research and debt repayment, reversing a previous 51% drop.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Salarius Pharmaceuticals Inc (SLRX) stock price today?

The current price of SLRX is 0.8705 USD — it has increased 1.28 % in the last trading day.

arrow icon

What is Salarius Pharmaceuticals Inc (SLRX)'s business?

Salarius Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on advancing its pipeline of peptide conjugate therapeutics engineered through its IMP3ACT platform that reduces the complexity of drug development and manufacturing. It is focused on developing effective treatments for patients with cancer with high, unmet medical needs. The company’s lead candidate, seclidemstat (SP-2577), is being studied as treatment for pediatric cancers, sarcomas, and other cancers with limited treatment options. Its pipeline consists of SP-3164 a targeted protein degrader and seclidemstat (SP-2577), a targeted protein inhibitor. SP-3164 is a next-generation cereblon-binding MG. SP-2577 is a small-molecule LSD1 inhibitor with a novel scaffold.

arrow icon

What is the price predicton of SLRX Stock?

Wall Street analysts forecast SLRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for SLRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Salarius Pharmaceuticals Inc (SLRX)'s revenue for the last quarter?

Salarius Pharmaceuticals Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Salarius Pharmaceuticals Inc (SLRX)'s earnings per share (EPS) for the last quarter?

Salarius Pharmaceuticals Inc. EPS for the last quarter amounts to -1.81 USD, decreased -84.09 % YoY.

arrow icon

What changes have occurred in the market's expectations for Salarius Pharmaceuticals Inc (SLRX)'s fundamentals?

The market is revising No Change the revenue expectations for Salarius Pharmaceuticals, Inc. (SLRX) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -81.52%.
arrow icon

How many employees does Salarius Pharmaceuticals Inc (SLRX). have?

Salarius Pharmaceuticals Inc (SLRX) has 2 emplpoyees as of December 05 2025.

arrow icon

What is Salarius Pharmaceuticals Inc (SLRX) market cap?

Today SLRX has the market capitalization of 5.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free